Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 7/20 | 0.61 |
| ▸ | CHRM2 | P08172 | 7/20 | 0.61 |
| ▸ | CHRM3 | P20309 | 4/20 | 0.55 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.54 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.53 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.51 |
| ▸ | DRD2 | P14416 | 1/20 | 0.51 |
| ▸ | DRD4 | P21917 | 1/20 | 0.51 |
| ▸ | UBE2M | P61081 | 1/20 | 0.50 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.50 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.49 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23744640 | 0.89 | CHRM2 (0.77) | CHRM1CHRM2CHRM3CHRM5CHRM4 | |
| SCHEMBL23744585 | 0.89 | CHRM2 (0.77) | CHRM1CHRM2CHRM3CHRM5CHRM4 | |
| SCHEMBL26088912 | 0.87 | CHRM1 (0.51) | CHRM1CHRM2CHRM3SIGMAR1CHRM5 | |
| SCHEMBL23744495 | 0.85 | CHRM3 (0.69) | CHRM1CHRM2CHRM3CHRM5CHRM4 | |
| SCHEMBL23744150 | 0.85 | CHRM2 (0.75) | CHRM1CHRM2CHRM3SIGMAR1CHRM5 | |
| SCHEMBL23744148 | 0.84 | SIGMAR1 (0.52) | CHRM1CHRM2CHRM3SIGMAR1CHRM5 | |
| SCHEMBL26430595 | 0.84 | SIGMAR1 (0.52) | CHRM1CHRM2CHRM3SIGMAR1CHRM5 | |
| SCHEMBL23744383 | 0.84 | CHRM2 (0.62) | CHRM1CHRM2CHRM3SIGMAR1CHRM5 | |
| SCHEMBL23744477 | 0.84 | CHRM1 (0.57) | CHRM1CHRM2CHRM3CHRM5CHRM4 | |
| SCHEMBL23744230 | 0.83 | CHRM2 (0.67) | CHRM1CHRM2CHRM3SIGMAR1CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230129359-A1 | MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE | NEUROCRINE BIOSCIENCES, INC. | 2023-04-27 | — | — | US | disclosed |
| WO-2021158698-A1 | MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE | NEUROCRINE BIOSCIENCES, INC. (US) | 2021-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230129359-A1 | MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE | CHRM4, CHRM2, CHRM5 | CHRM1 5/4885CHRM2 2/4885CHRM3 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.